Associations between MASLD phenotypes and the risk of carotid artery plaque: a cross-sectional study among railway workers
- PMID: 40553390
- DOI: 10.1007/s00592-025-02536-w
Associations between MASLD phenotypes and the risk of carotid artery plaque: a cross-sectional study among railway workers
Abstract
Aims: Current evidence on the association between metabolic dysfunction-associated steatotic liver disease (MASLD) phenotypes to carotid artery plaque (CAP) remains limited. This study aims to investigate both the association and the potential mediating effects of MASLD phenotypes on the risk of CAP.
Methods: In this cross-sectional study, 8644 participants were categorized into five groups based on hepatic steatosis and cardiometabolic criteria: Non-hepatic steatosis, Dysglycemia-MASLD, Overweight-MASLD, Lean-MASLD, and other hepatic steatosis. Multivariable logistic regression analysis was conducted to evaluate the association between MASLD phenotypes and CAP. Mediation analyses were performed to evaluate the mediating effect of dysglycemia and body mass index (BMI) on the relationship between MASLD and CAP.
Results: The Dysglycemia-MASLD group exhibited the highest prevalence of CAP of 26.28%, followed by the Lean-MASLD (18.55%) and Overweight-MASLD (14.39%) groups. After adjusting for covariates, Dysglycemia-MASLD patients had a significantly higher risk of CAP, with an OR of 1.599 (95% CI 1.348, 1.896). Notably, individuals under 45 in the Dysglycemia-MASLD and Lean-MASLD subgroups had more than a two-fold increased risk of CAP compared to the Non-hepatic steatosis group, with ORs of 2.393 (95% CI 1.660, 3.416) and 2.724 (95% CI 1.002, 6.221), respectively. Mediation analysis indicated that dysglycemia and BMI mediated 30.86% and 24.49% of the association of MASLD with CAP.
Conclusion: The risk of developing CAP varies across MASLD phenotypes, with Dysglycemia-MASLD and Lean-MASLD patients exhibiting the highest risk. Therefore, personalized health management strategies are essential for different MASLD phenotypes.
Keywords: Carotid artery plaque; Metabolic dysfunction-associated steatotic liver disease; Nonalcoholic fatty liver disease; Type 2 diabetes mellitus.
© 2025. Associazione Medici Diabetologi / Association of Diabetologists (AMD), Societa Italiana di Diabetologia / Italian Society of Diabetology (SID).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Ethics approval and human and animal rights: The study was performed in accordance with the 1964 Helsinki Declaration and its later amendments and was approved by the Ethical Committee of the Affiliated Hospital of Chengdu University approved this study (No. PJ 2019-015-02).
Similar articles
-
Association between Life's Crucial 9 and metabolic dysfunction-associated steatotic liver disease: the mediating role of neutrophil-percentage-to-albumin ratio.Front Nutr. 2025 Jun 6;12:1549089. doi: 10.3389/fnut.2025.1549089. eCollection 2025. Front Nutr. 2025. PMID: 40547368 Free PMC article.
-
Beyond BMI: revealing metabolic risk in lean MASLD.Arch Clin Cases. 2025 Aug 4;12(3):110-118. doi: 10.22551/2025.48.1203.10322. eCollection 2025. Arch Clin Cases. 2025. PMID: 40761878 Free PMC article.
-
[Associations of metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk factor abnormalities with adverse pregnancy outcomes].Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Jun 18;57(3):487-495. doi: 10.19723/j.issn.1671-167X.2025.03.012. Beijing Da Xue Xue Bao Yi Xue Ban. 2025. PMID: 40509826 Free PMC article. Chinese.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79(6):1542–1556. https://doi.org/10.1016/j.jhep.2023.06.003 - DOI - PubMed
-
- Lee BP, Dodge JL, Terrault NA (2024) National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology 79(3):666–673. https://doi.org/10.1097/hep.0000000000000604 - DOI - PubMed
-
- Pan J, Yang B, Wang Z, Tang L, Jia P, Yang S et al (2023) Triglyceride-glucose index is related to carotid artery plaque in railway workers: a cross-sectional study. Diabetes Metab Syndr Obes 16:2561–2571. https://doi.org/10.2147/DMSO.S418358 - DOI - PubMed - PMC
-
- Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B et al (2018) Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care 41(2):341–347. https://doi.org/10.2337/dc17-1590 - DOI - PubMed
-
- Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA, D’Agostino RB Sr (2011) Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 365(3):213–221. https://doi.org/10.1056/NEJMoa1012592 - DOI - PubMed - PMC
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous